AbbVie has developed the BRAIN (Breakthrough Innovation for CNS Delivery) platform, a comprehensive technology suite designed to overcome the blood-brain barrier (BBB) challenge in CNS drug development. The platform integrates multiple delivery approaches including advanced Fc engineering, novel antibody formats, and receptor-mediated transcytosis (RMT) strategies to enable therapeutic antibodies to reach the brain at pharmacologically relevant concentrations [1].
The BRAIN platform represents AbbVie's strategic approach to addressing the high failure rate and limited efficacy of CNS therapeutics. By enhancing brain penetration, AbbVie aims to develop disease-modifying therapies for Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders where traditional antibody approaches have been limited by poor BBB penetration [2].
AbbVie's BRAIN platform employs sophisticated Fc engineering to optimize brain exposure:
| Modification | Function | Benefit |
|---|---|---|
| FcRn binding enhancement | Extended serum half-life | Sustained brain delivery |
| FcγR attenuation | Reduced effector function | Lower ARIA risk |
| pH-optimized binding | Target release at brain pH | Enhanced brain retention |
| Glycoengineering | Optimized pharmacokinetics | Improved CNS exposure |
These modifications enable antibody therapeutics to achieve therapeutic concentrations in the brain at doses that are practically and economically feasible [3].
The BRAIN platform supports multiple antibody formats:
AbbVie is developing RMT-enabled antibodies:
| Program | Target | Stage | Approach |
|---|---|---|---|
| ABBV-8E12 (Tilavonemab) | Tau aggregates | Phase 2 | Antibody |
| ABBV-951 | Tau | Preclinical | BRAIN platform |
| Undisclosed | pTau | Discovery | Bispecific |
ABBV-8E12 (Tilavonemab): Anti-tau antibody that demonstrated safety in Phase 1/2 but did not meet primary endpoints in Phase 2 LILLY studies. Program continues to evaluate alternative dosing and patient selection strategies [5].
| Program | Target | Stage | Approach |
|---|---|---|---|
| ABBV-951 | α-synuclein | Phase 1 | Antibody |
| ABBV-3B | α-synuclein | Discovery | BRAIN platform |
AbbVie's α-synuclein programs aim to:
The BRAIN platform also supports programs targeting neuroinflammation:
| Company/Platform | Primary Approach | Key Features | Clinical Stage |
|---|---|---|---|
| AbbVie BRAIN | Fc engineering + RMT | Multiple formats | Phase 1/2 |
| Roche TfR | Bispecific TfR | High brain exposure | Phase 1/2 |
| Eli Lilly | Fc engineering | Established platform | Approved (donanemab) |
| J&J | RMT platform | Single domain | Preclinical |
| Lundbeck/Genentech | Bispecific | Dual-targeting | Preclinical |
AbbVie's differentiating factors:
Tau protein represents a key target for Alzheimer's disease:
α-Synuclein is central to Parkinson's disease:
Microglial targets represent a third pillar:
AbbVie's CNS programs focus on:
The BRAIN platform enables:
AbbVie has established collaborations to enhance CNS delivery: